RealFeedApp beta

Terumo BCT automates TIL production

Terumo Blood and Cell Technologies partners with TrAMPoline Pharma and the University of Colorado to use the Quantum Flex™ Cell Expansion System for automated TIL manufacturing. The goal is to bridge the gap between lab development and clinical scale while preserving product quality.

Field
gene therapy
What they did
Terumo BCT, in partnership with TrAMPoline Pharma and the University of Colorado, is developing an automated system to manufacture genetically engineered Tumor-Infiltrating Lymphocytes (TILs) for cancer treatment.
Why it matters
Automation is intended to bridge the gap between laboratory development and clinical scale by using scalable technology for both phases, thereby preserving product quality throughout the development pipeline.
#til#cell therapy#automation#terumo bct#gene editing

Read the original →